Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...
Biotech
Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...
Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round
China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...
Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...
Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...
BRL Medicine Raises RMB 200M in Series B Financing for CGT Development
BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly...
Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab
Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...
Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...
Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs
Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB...
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...
Organon Signs MOU with China’s National Health Commission at CIIE
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...
CIIE: Bo’ao Lecheng Zone Announces Partnerships with Multinationals
The 5th China International Import Expo (CIIE) saw the Bo’ao Lecheng Medical Tourism Pilot Zone...
Novatim Immune Therapeutics Raises RMB 500M in First Financing Round
China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...
Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...
Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA
China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...
Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...
Antengene’s ATG-017 Gets FDA Approval for Phase I Clinical Study
Antengene Corporation has announced receiving approval from the US Food and Drug Administration (FDA) to...
Shandong Buchang Partners with REMD Bio for Bispecific Antibody Development
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced a co-development and licensing agreement...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...